Sarepta Therapeutics Appoints Deirdre Connelly to Its Board of Directors
Monday, 16 September 2024, 05:29
Board Appointment Announcement
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, today announced the appointment of Deirdre P. Connelly to its Board of Directors. Ms. Connelly is a highly accomplished medical executive with a rich history in the biopharmaceutical industry.
Experience and Impact
- Ms. Connelly has held senior leadership roles in several leading pharmaceutical companies.
- Her expertise is expected to drive innovation and strategy within Sarepta Therapeutics.
- With her on board, Sarepta aims to strengthen its focus on genetic treatments.
This strategic appointment reflects Sarepta’s commitment to enhancing its leadership in the field of genetic medicine.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.